ReviewThrombosis update2022
The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges.
Review in Thrombosis update, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 20 citations in OpenAlex.
- Molecular determinants of thromboinflammatory activation in inflammatory bowel disease.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Elevated Risk of Acute Urine Retention in Patients with Symptomatic Benign Prostate Hyperplasia Following Coronavirus Disease 2019 Infection: A Retrospective Cohort Study from TriNetX.Life (Basel, Switzerland) · 2026Article
- COVID-19, the disease that changed the world.Medicine and pharmacy reports · 2026Review
- Type 2 Diabetes Is Associated with Increased Coagulation Activity in Patients with Atrial Fibrillation: A D-Dimer-Based Analysis.Biomedicines · 2026Article
- Thromboinflammation in dogs with virulent babesiosis.Frontiers in veterinary science · 2026Article
- Article
- Pulmonary embolism in a post-COVID-19 patient: a critical diagnostic challenge.Journal of medicine and life · 2025Article
- Hematologic and Immunologic Overlap Between COVID-19 and Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2025Review
- Challenges and Opportunities of Direct Oral Anticoagulant (DOAC) Therapy in Complex Clinical Scenarios: A Comprehensive Review and Practical Guide.Journal of clinical medicine · 2025Review
- Stroke Prognosis: The Impact of Combined Thrombotic, Lipid, and Inflammatory Markers.Journal of atherosclerosis and thrombosis · 2025Article
- Sialyl LewisACS medicinal chemistry letters · 2025Article
- COVID-19: a vascular nightmare unfolding.Frontiers in immunology · 2025Review
- Thromboembolic Events in the Era of COVID-19: A Detailed Narrative Review.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Review
- The impact of COVID-19 hospitalizations on nursing home admissions: a regional insight into long-term care and public health.Frontiers in public health · 2025Article
- IL 6 Cascade in Post COVID Cardiovascular Complications: A Review of Endothelial Injury and Clotting Pathways.Cardiovascular & hematological disorders drug targets · 2025Review
- Baseline level of interleukin-6 is associated with the risk of acute coronary syndrome development in SARS-CoV-2 infection.BMC cardiovascular disorders · 2024Article
- The Long-Term Cardiovascular Impact of COVID-19: Pathophysiology, Clinical Manifestations, and Management.Cureus · 2024Review
- Integrating network pharmacology and experimental verification to reveal the anti-inflammatory ingredients and molecular mechanism of pycnogenol.Frontiers in pharmacology · 2024Article
- Inflammation and Coagulation are Two Interconnected Pathophysiological Pathways in Atrial Fibrillation Pathogenesis.Journal of inflammation research · 2023Article
- Investigation of Two Potential Predictors of Thrombosis Risk in Polycythemia Vera: Hematocrit-to-Hemoglobin Ratio and HALP Score.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19), caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can cause life-threatening pathology characterized by a dysregulated immune response and coagulopathy. While respiratory failure induced by inflammation is the most common cause of death, micro-and macrovascular thrombosis leading to multiple organ failure are also causes of mortality. Dysregulation of systemic inflammation observed in severe COVID-19 patients is manifested by cytokine release syndrome (CRS) - the aberrant release of high levels of proinflammatory cytokines, such as IL-6, IL-1, TNFα, MP-1, as well as complement. CRS is often accompanied by activation of endothelial cells and platelets, coupled with perturbation of the balance between the pro-and antithrombotic mechanisms, resulting in thrombosis. Inflammation and thrombosis form a vicious circle, contributing to morbidity and mortality. Treatment of hyperinflammation has been shown to decrease thrombosis, while anti-thrombotic treatment also downregulates cytokine release. This review highlights the relationship between COVID-19-mediated systemic inflammation and thrombosis, the molecular pathways involved, the therapies targeting these processes, and the challenges currently encountered.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.